Perspectives and gaps in the management of food allergy and anaphylaxis in the Asia-Pacific Region.

Food allergy adrenaline autoinjector allergist allergy service anaphylaxis

Journal

The journal of allergy and clinical immunology. Global
ISSN: 2772-8293
Titre abrégé: J Allergy Clin Immunol Glob
Pays: United States
ID NLM: 9918453488706676

Informations de publication

Date de publication:
May 2024
Historique:
received: 25 05 2023
revised: 03 10 2023
accepted: 08 10 2023
medline: 29 1 2024
pubmed: 29 1 2024
entrez: 29 1 2024
Statut: epublish

Résumé

Food allergy (FA), which is a condition that has no effective cure and can result in severe life-threatening allergic reactions, remains a global public health concern; however, little is known about how FAs are currently managed in the Asia-Pacific region. The main objective of this survey was to evaluate the epidemiology of FA, as well as the availability of resources and practices for management of FA and anaphylaxis by health care providers across Asia. From June 2022 to September 2022, a questionnaire-based survey comprising 66 questions was electronically sent to member societies of the Asia Pacific Association of Allergy Asthma and Clinical Immunology by using Survey Monkey. A total of 20 responses were received from 15 member countries and territories. Compared with the pediatric data, there was a lack of prevalence data for FA in adults. Except for Australia and Japan, most regions had between 0.1 and 0.5 allergists per 100,000 population and some had fewer than 0.1 allergists per 100,000 population. The perceived rate of FA in regions with a short supply of allergists was high. Although specific IgE tests and oral food challenges were available in all regions, the median wait time for oral food challenges at government facilities was 37 days (interquartile range = 10.5-60 days). Seven regions still relied on prescriptions of ampules and syringes of injectable adrenaline, and adrenaline autoinjectors were not accessible in 4 regions. Oral immunotherapy as FA treatment was available in half of the surveyed countries and territories. Our study offers a cross-sectional evaluation of the management practices for FA in each Asia Pacific Association of Allergy Asthma and Clinical Immunology member country or territory. Urgent actions are required to enhance allergy services, improve the accessibility and affordability of adrenaline autoinjectors, and conduct robust epidemiologic studies.

Sections du résumé

Background UNASSIGNED
Food allergy (FA), which is a condition that has no effective cure and can result in severe life-threatening allergic reactions, remains a global public health concern; however, little is known about how FAs are currently managed in the Asia-Pacific region.
Objective UNASSIGNED
The main objective of this survey was to evaluate the epidemiology of FA, as well as the availability of resources and practices for management of FA and anaphylaxis by health care providers across Asia.
Methods UNASSIGNED
From June 2022 to September 2022, a questionnaire-based survey comprising 66 questions was electronically sent to member societies of the Asia Pacific Association of Allergy Asthma and Clinical Immunology by using Survey Monkey.
Results UNASSIGNED
A total of 20 responses were received from 15 member countries and territories. Compared with the pediatric data, there was a lack of prevalence data for FA in adults. Except for Australia and Japan, most regions had between 0.1 and 0.5 allergists per 100,000 population and some had fewer than 0.1 allergists per 100,000 population. The perceived rate of FA in regions with a short supply of allergists was high. Although specific IgE tests and oral food challenges were available in all regions, the median wait time for oral food challenges at government facilities was 37 days (interquartile range = 10.5-60 days). Seven regions still relied on prescriptions of ampules and syringes of injectable adrenaline, and adrenaline autoinjectors were not accessible in 4 regions. Oral immunotherapy as FA treatment was available in half of the surveyed countries and territories.
Conclusions UNASSIGNED
Our study offers a cross-sectional evaluation of the management practices for FA in each Asia Pacific Association of Allergy Asthma and Clinical Immunology member country or territory. Urgent actions are required to enhance allergy services, improve the accessibility and affordability of adrenaline autoinjectors, and conduct robust epidemiologic studies.

Identifiants

DOI: 10.1016/j.jacig.2023.100202 PMID: 38283085 PMC: PMC10818080
pubmed: 38283085
doi: 10.1016/j.jacig.2023.100202
pii: S2772-8293(23)00127-3
pmc: PMC10818080
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100202

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Auteurs

Agnes Sze Yin Leung (ASY)

Department of Paediatrics, Prince of Wales Hospital, Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong, China.

Ruby Pawankar (R)

Division of Allergy, Department of Pediatrics, Nippon Medical School, Tokyo, Japan.

Punchama Pacharn (P)

Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Lydia Su Yin Wong (LSY)

Department of Paediatrics, Yong Loo Lin School of Medicine and Khoo Teck Puat-National University Children's Medical Institute, National University of Singapore, Singapore, Singapore.

Duy Le Pham (D)

University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.

Grace Chan (G)

Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.

Iris Rengganis (I)

Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo National Hospital, Jakarta, Indonesia.

Jing Zhao (J)

Capital Institute of Pediatrics in China, Beijing, China.

Jiu Yao Wang (JY)

Division of Allergy and Clinical Immunology, Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Kent Chee-Keen Woo (KC)

Gleneagles Hospital, Kuala Lumpur, Malaysia.

Komei Ito (K)

Allergy and Immunology Center, Aichi Children's Health And Medical Center, Aichi, Japan.

Kyunguk Jeong (K)

Ajou University School of Medicine, Suwon, Korea.

Marysia Recto (M)

Division of Adult and Pediatric Allergy and Immunology, University of the Philippines College of Medicine, Philippine General Hospital, Manila, Philippines.

Michaela Lucas (M)

WA Health and University of Western Australia, Perth, Australia.

Mizuho Nagao (M)

National Hospital Organization Mie National Hospital, Tsu, Japan.

Rommel Crisenio M Lobo (RCM)

Fe del Mundo Medical Center, Metro Manila, Manila, Philippines.

Sonomjamts Munkhbayarlakh (S)

Department of Pulmonology and Allergology, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.

Sumadiono Sumadiono (S)

Department of Child Health, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Syed Rezaul Huq (SR)

National Institute of the Chest Disease and Hospital NIDCH Mohakhali, Dhaka, Bangladesh.

Thushali Ranasinghe (T)

Allergy, Immunology and Cell Biology Unit, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Mimi Tang (M)

Allergy Immunology, Murdoch Children's Research Institute, Department of Allergy and Immunology, The Royal Children's Hospital Melbourne, Melbourne, Australia.

Classifications MeSH